DoJ Expanding False Claims Cases Into New Areas Left Before To FDA
Executive Summary
The Department of Justice is going after pharmaceutical companies for behavior that traditionally has been left to FDA for regulatory enforcement.
You may also be interested in...
"Any Little Opening": Whistleblowers Target New Kinds Of Pharma Conduct
Pharmaceutical companies have overhauled their marketing practices but continue to be hit with qui tam suits as whistleblowers come up with new kinds of claims against them.
"Any Little Opening": Whistleblowers Target New Kinds Of Pharma Conduct
Pharmaceutical companies have overhauled their marketing practices but continue to be hit with qui tam suits as whistleblowers come up with new kinds of claims against them.
GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud
GlaxoSmithKline’s $750 million settlement with the Department of Justice raises a worrisome question for industry: will violations of current good manufacturing practices become a target for whistleblower suits?